BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16428940)

  • 1. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
    Shord SS; Thompson DM; Krempl GA; Hanigan MH
    Anticancer Drugs; 2006 Feb; 17(2):207-15. PubMed ID: 16428940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
    Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
    Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
    Lin A; Jabbari S; Worden FP; Bradford CR; Chepeha DB; Teknos TN; Liao JJ; Nyquist GG; Tsien C; Schipper MJ; Urba S; Wolf GT; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1413-8. PubMed ID: 16109461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
    Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
    Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
    Prasaja Y; Sutandyo N; Andrajati R
    Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
    Dimery IW; Legha SS
    J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
    Merouani A; Davidson SA; Schrier RW
    Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
    Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.
    Ghonaim E; El-Haggar S; Gohar S
    Med Oncol; 2021 Aug; 38(9):108. PubMed ID: 34357466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-induced human peripheral blood mononuclear cells' oxidative stress and nephrotoxicity in head and neck cancer patients: the influence of hydrogen peroxide.
    Quintanilha JCF; Visacri MB; Sousa VM; Bastos LB; Vaz CO; Guarnieri JPO; Amaral LS; Malaguti C; Lima CSP; Vercesi AE; Moriel P
    Mol Cell Biochem; 2018 Mar; 440(1-2):139-145. PubMed ID: 28828710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
    Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
    Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.
    Stinson J; Chan K; Lee J; Chow R; Cheon P; Giotis A; Pasetka M; Wan BA; Chow E; DeAngelis C
    Ann Palliat Med; 2017 Aug; 6(Suppl 1):S13-S20. PubMed ID: 28595433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
    Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
    J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
    Hinai Y; Motoyama S; Niioka T; Miura M
    J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
    Denham JW; Abbott RL
    J Clin Oncol; 1991 Mar; 9(3):458-63. PubMed ID: 1999716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.